HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream.

AbstractBACKGROUND:
Acne vulgaris is a disorder of the pilosebaceous unit in which the androgens contribute to its onset and persistence. The use of antiandrogens is therefore potentially effective; however, antiandrogens for topical use are not available on the market. Cortexolone 17α-propionate (CB-03-01; Cosmo S.p.A, Lainate, Italy) is a new potent topical antiandrogen potentially useful in acne vulgaris.
OBJECTIVES:
To evaluate the safety and the topical efficacy of CB-03-01 1% cream in acne vulgaris as compared with placebo and with tretinoin 0·05% cream (Retin-A® ; Janssen-Cilag).
METHODS:
Seventy-seven men with facial acne scored 2-3 according to Investigator's Global Assessment (IGA) were randomized to receive placebo cream (n = 15), or CB-03-01 1% cream (n = 30), or tretinoin 0·05% cream (n = 32) once a day at bedtime for 8 weeks. Clinical efficacy was evaluated every 2 weeks including total lesion count (TLC), inflammatory lesion count (ILC), acne severity index (ASI) and IGA. Safety assessment included local irritancy score, laboratory tests, physical examination, vital signs and recording of adverse events.
RESULTS:
CB-03-01 1% cream was very well tolerated, and was significantly better than placebo regarding TLC (P = 0·0017), ILC (P = 0·0134) and ASI (P = 0·0090), and also clinically more effective than comparator. The product also induced a faster attainment of 50% improvement in all the above parameters.
CONCLUSIONS:
This pilot study supports the rationale for the use of topical antiandrogens in the treatment of acne vulgaris. CB-03-01 1% cream seems to fit with the profile of an ideal antiandrogen for topical use.
AuthorsV Trifu, G-S Tiplica, E Naumescu, L Zalupca, L Moro, G Celasco
JournalThe British journal of dermatology (Br J Dermatol) Vol. 165 Issue 1 Pg. 177-83 (Jul 2011) ISSN: 1365-2133 [Electronic] England
PMID21428978 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.
Chemical References
  • Androgen Antagonists
  • Anti-Inflammatory Agents
  • Emollients
  • Keratolytic Agents
  • Propionates
  • Tretinoin
  • Cortodoxone
  • Clascoterone
Topics
  • Acne Vulgaris (drug therapy, pathology)
  • Administration, Topical
  • Adolescent
  • Adult
  • Androgen Antagonists (therapeutic use)
  • Anti-Inflammatory Agents (therapeutic use)
  • Cortodoxone (analogs & derivatives, therapeutic use)
  • Double-Blind Method
  • Emollients (therapeutic use)
  • Humans
  • Keratolytic Agents (therapeutic use)
  • Male
  • Middle Aged
  • Pilot Projects
  • Propionates (therapeutic use)
  • Severity of Illness Index
  • Tretinoin (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: